Antimicrobial Stewardship

AMR is undermining modern medicine and putting patients at risk of premature death. bioMérieux provides comprehensive and complimentary solutions to help save lives.

Each Year in the U.S.:

Diagnostics and Antimicrobial Stewardship

Antimicrobial stewardship is a commitment to preserving drug efficacy for future generations through appropriate use of antimicrobial drugs. Our diagnostic solutions support the "five rights" of medication administration: right drug, right patient, right dose, right time, and right route.

Partner With Us

Antimicrobial stewardship programs provide a framework for healthcare systems to better protect patients from the harms of unnecessary antibiotic use and antimicrobial resistance. According to the CDC, roughly 85% of U.S. acute care hospitals have antimicrobial stewardship programs that rely on the CDC’s seven Core Elements of Hospital Antibiotic Stewardship. As a leader in the field of in vitro diagnostics and antimicrobial stewardship, bioMérieux partners with U.S. healthcare systems to enhance the continuum of care and increase the economic value of stewardship. To do so, we integrate fast and actionable diagnostics, expert consultancy services, and an unmatched advanced analytic platform.

bioMérieux is the trusted partner that today’s healthcare systems need to confidently deliver improved clinical outcomes and support stewardship programs.

Diagnostics and data-driven tools help clinicians determine appropriate treatment which aid to reduce the spread of antibiotic-resistant infections. As the largest in vitro diagnostics company committed to antimicrobial stewardship, we help maximize the use of diagnostic solutions to detect, identify, and treat today's most urgent drug-resistant pathogens. 80% of our existing diagnostic products and 75% of our research and development budget are dedicated to the fight against antimicrobial resistance.

 

DIAGNOSTICS TO IMPROVE ANTIBIOTIC USE

It is important to obtain an early and accurate diagnosis which is helpful in improving patient outcomes. Our diagnostic systems assist clinical labs with reducing the time required for detection, identification, and susceptibility testing.

BIOFIRE® FILMARRAY®

BACT/ALERT® VIRTUO®

VITEK® MS

VITEK® 2

ETEST®

RAPIDEC® CARBA NP

API®

VIDAS ®

ADVANCED ANALYTICS TO SUPPORT TIMELY CLINICAL DECISIONS

We support healthcare systems in their efforts to deliver evidence-based clinical care with our analytic platforms that help to optimize efficiency and increase collaborative communication.

MYLA®

CLARION™

BIOMÉRIEUX EPISEQ® CS

CONSULTANCY SERVICES TO ADVANCE STEWARDSHIP INITIATIVES

Our expertise in microbiology and infectious diseases, coupled with our collaborative Lab Optimization Consultancy and Stewardship Consultancy practices, enables us to help our partners understand their real processes—then visualize, analyze, and apply data, to support positive patient outcomes. Our partnership approach reveals best practices that can improve patient care, and contribute to economically sustainable healthcare systems by creating ways to maintain lower costs.


Lab Optimization Consultancy

With our patient-centric approach, we help laboratories optimize and transform their workflow to support clinical decisions and better patient outcomes. Relevant and timely results have become key in the race to be more efficient and control costs. This elevates the important role the laboratory plays in the value-based healthcare model.

DOWNLOAD THE LAB OPTIMIZATION BROCHURE

Stewardship Consultancy

Our customer-centric approach, teamed with our extensive knowledge and experience, means that we see things from a unique angle and can provide consultancy to support stewardship programs with cross-departmental impact. We help hospitals execute and improve antimicrobial stewardship through actionable road maps and discovery of dynamic insights.

 

Fighting Antimicrobial Resistance is a Growing Concern

bioMérieux is actively engaged in activities that support the multipronged approach that is needed to mitigate the rise of antimicrobial resistance. We continue to expand our impact outside of the clinical laboratory, establishing and contributing to partnerships that provide educational resources and advocate for diagnostics among stewardship teams, patients, and government policymakers.

 



AMR and Stewardship Resources

The Cost of AMR

What Can Antibiotics Treat?

AMR Timeline

Stewardship Education Opportunities

bioMérieux Connection Blog

Visit the Virtual Learning Lounge

FIGHT BACK Against AMR

External Partner Resources

As a proud member of the AMR Industry Alliance, we invite you to view the 2020 Progress Report which provides a snap shot of the life sciences industry's collective efforts and leadership in tackling the rise of antimicrobial resistance. 

 

In November 2019, the Centers for Disease Control updated the Core Elements of Hospital Antibiotic Stewardship Programs to reflect key learnings and evidence, further advancing the viability of stewardship programs in the United States.

 

bioMérieux supports CIDRAP with grants for the Antimicrobial Stewardship Project (ASP). We encourage you to visit the Center for Infectious Disease Research and Policy's ASP page to view the latest industry news and updates about stewardship in the United States.

 

The AMR Challenge was a year long effort conducted by the U.S. government to accelerate the fight against AMR. bioMérieux is proud to have been a participant and to have helped promote and encourage the One Health approach.

 

bioMérieux is proud to be a co-leader in the VALUE-Dx project, a consortium of 26 partners which aims to demonstrate the medical and economic value of diagnostics to combat antibiotics resistance.

 

 

References:

  1. Review on Antimicrobial Resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Available at https://amr-review.org/sites/default/files/AMR. Accessed on Sep. 23, 2020.
  2. Clancy CJ, Ngguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clinical Infectious Dis 2020. doi/10.1093/cid/ciaa524/5828436. 
  3. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019. Available at: cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed Sep. 3, 2020.
  4. bioMérieux. 2020 Annual Report.; 2020:19. Available at: https://www.biomerieux.com/sites/corporate/files/annual-report-biomerieux-2020-en-0.pdf#page=19. Accessed Sep. 16, 2021.

PRN 057494 Rev2.0A

 

Pioneering Diagnostics